litlas
Log inCreate account

Gregory A. Daniels

Active 1978–2025

59
Papers
18,078
Citations
39
h-index
55
i10-index

Citations

Citations per year for Gregory A. Daniels1990: 1 citations1992: 1 citations1994: 1 citations1995: 1 citations1997: 3 citations1998: 3 citations2000: 4 citations2001: 8 citations2002: 5 citations2003: 5 citations2004: 6 citations2005: 11 citations2006: 11 citations2007: 11 citations2008: 6 citations2009: 6 citations2010: 13 citations2011: 18 citations2012: 24 citations2013: 45 citations2014: 57 citations2015: 110 citations2016: 154 citations2017: 172 citations2018: 256 citations2019: 787 citations2020: 1,177 citations2021: 1,200 citations2022: 1,037 citations2023: 767 citations2024: 1,069 citations2025: 504 citations2026: 17 citations1991: no citations, so this year is not shown1993: no citations, so this year is not shown1996: no citations, so this year is not shown1999: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,023 citing papers, 27.2% of this breakdownChina: 1,453 citing papers, 13.1% of this breakdownGermany: 628 citing papers, 5.6% of this breakdownUnited Kingdom: 608 citing papers, 5.5% of this breakdownItaly: 573 citing papers, 5.1% of this breakdownFrance: 463 citing papers, 4.2% of this breakdownAustralia: 456 citing papers, 4.1% of this breakdownNetherlands: 359 citing papers, 3.2% of this breakdownCanada: 326 citing papers, 2.9% of this breakdownSpain: 312 citing papers, 2.8% of this breakdownJapan: 302 citing papers, 2.7% of this breakdownSwitzerland: 299 citing papers, 2.7% of this breakdown
0%27.2%Other 20.9%

Institutions

Fields

  • Medicine55.8%
  • Biochemistry, Genetics and Molecular Biology32.1%
  • Immunology and Microbiology9%
  • Engineering0.9%
  • Computer Science0.4%
  • Materials Science0.4%
  • Other1.4%

Topics

  • Cancer Immunotherapy and Biomarkers14.2%
  • CAR-T cell therapy research7.7%
  • Immunotherapy and Immune Responses7.4%
  • Cancer Genomics and Diagnostics4.1%
  • Virus-based gene therapy research3.4%
  • Cutaneous Melanoma Detection and Management3.3%
  • Other59.9%

Coauthors

All papers

Open in search
  1. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Authors: James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, David Hogg, Andrew F. Hill, Iván Márquez‐Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Célèste Lebbé, Grant A. McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Lars Bastholt, Jasmine I. Rizzo, Ágnes Balogh, Andriy Moshyk, F. Stephen Hodi, Jedd D. Wolchok - New England Journal of Medicine 2019 cited by 3,708

  2. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

    Authors: Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Marcus O. Butler, Andrew Hill, Iván Márquez‐Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Célèste Lebbé, Grant A. McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Tuba Öcek Baş, Corey Ritchings, James Larkin, F. Stephen Hodi - Journal of Clinical Oncology 2021 cited by 1,104

  3. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Authors: Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A. Delman, Lynn E. S̄pitler, Igor Puzanov, Sanjiv S. Agarwala, Mohammed Milhem, Lee D. Cranmer, Brendan D. Curti, Karl D. Lewis, Merrick I. Ross, Troy H. Guthrie, Gerald P. Linette, Gregory A. Daniels, Kevin J. Harrington, Mark R. Middleton, Wilson H. Miller, Jonathan S. Zager, Yining Ye, Bin Yao, Li Ai, Susan Doleman, Ari M. Vanderwalde, Jennifer Gansert, Robert S. Coffin - Journal of Clinical Oncology 2015 cited by 2,598

  4. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

    Authors: Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip Pravin Patel, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock - Molecular Cancer Therapeutics 2017 cited by 2,390

  5. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells

    Authors: Daniel Ramsköld, Shujun Luo, Yu-Chieh Wang, Robin Li, Qiaolin Deng, Omid R. Faridani, Gregory A. Daniels, Irina Khrebtukova, Jeanne F. Loring, Louise C. Laurent, Gary P. Schroth, Rickard Sandberg - Nature Biotechnology 2012 cited by 1,664

  6. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

    Authors: Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang, Karl D. Lewis, Chrysalyne D. Schmults, Leonel F. Hernandez‐Aya, Friedegund Meier, Dirk Schadendorf, Alexander Guminski, Axel Hauschild, Deborah Jean Lee Wong, Gregory A. Daniels, Carola Berking, Vladimir Janković, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Matthew G. Fury, Danny Rischin - The Lancet Oncology 2020 cited by 480

  7. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

    Authors: Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden, Deborah Jean Lee Wong, Douglas R. Adkins, Paul Swiecicki, Wanxing Chai‐Ho, Peter Oppelt, Debanjali Ghosh, Julie Bykowski, Alfredo Molinolo, Emily Pittman, Mónica V. Estrada, Kathryn A. Gold, Gregory A. Daniels, Scott M. Lippman, Amanda Natsuhara, Karen Messer, Ezra E.W. Cohen - The Lancet Oncology 2021 cited by 258

  8. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

    Authors: Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi, Joseph J. Drabick, Minal Barve, Gregory A. Daniels, Deborah Jean Lee Wong, Emmett V. Schmidt, Albert F. Candia, Robert L. Coffman, Abraham C.F. Leung, Robert S. Janssen - Cancer Discovery 2018 cited by 341

  9. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

    Authors: Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald Miletello, Mayer Fishman, René González, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott - Journal for ImmunoTherapy of Cancer 2019 cited by 147

  10. Dabrafenib Versus Dabrafenib + Trametinib in BRAF -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial

    Authors: Naifa L. Busaidy, Bhavana Konda, Lai Wei, Lori J. Wirth, Catherine Devine, Gregory A. Daniels, Jonas DeSouza, Ming Poi, Nathan D. Seligson, Maria E. Cabanillas, Jennifer A. Sipos, Matthew D. Ringel, Ann‐Kathrin Eisfeld, Cynthia Timmers, Manisha H. Shah - Thyroid 2022 cited by 106

  11. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma

    Authors: Robert H. I. Andtbacka, Brendan Curti, Gregory A. Daniels, Sigrun Hallmeyer, Eric D. Whitman, Jose Lutzky, Lynn E. Spitler, Karl Zhou, Praveen K. Bommareddy, Mark Grose, Meihua Wang, Cai Wu, Howard L. Kaufman - Journal of Clinical Oncology 2021 cited by 94

  12. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

    Authors: Ezra E.W. Cohen, Lisle Nabell, Deborah J. Wong, Terry Day, Gregory A. Daniels, Mohammed Milhem, Sanjeev Deva, Michael Jameson, Orlando Guntinas-Lichius, Mohammed Almubarak, Matthew Strother, Eric Whitman, Michael Chisamore, Cynthia Obiozor, Teresa Bagulho, Jose Gomez-Romo, Cristiana Guiducci, Robert Janssen, Erick Gamelin, Alain P. Algazi - Clinical Cancer Research 2021 cited by 48

  13. Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Authors: Neil Senzer, Howard L. Kaufman, Thomas Amatruda, Mike Nemunaitis, Tony Reid, Gregory A. Daniels, René González, John A. Glaspy, Eric D. Whitman, Kevin J. Harrington, Howard Goldsweig, Tracey Marshall, Colin Love, Robert S. Coffin, John Nemunaitis - Journal of Clinical Oncology 2009 cited by 615

  14. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

    Authors: Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher A. Barker, William E. Carson, Carlo M. Contreras, Gregory A. Daniels, Dominick J. DiMaio, Ryan C. Fields, Martin D. Fleming, Morganna Freeman, Anjela Galan, Brian Gastman, Valerie Guild, Douglas B. Johnson, Richard W. Joseph, Julie R. Lange, Sameer K. Nath, Anthony J. Olszanski, Patrick A. Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K.S. Salama, Joseph J. Skitzki, Jeffrey A. Sosman, Susan M. Swetter, Kenneth K. Tanabe, Evan Wuthrick, Nicole R. McMillian, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2019 cited by 438

  15. Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

    Authors: Thinle Chodon, Begoña Comı́n-Anduix, Bartosz Chmielowski, Richard C. Koya, Zhongqi Wu, Martin Auerbach, Charles Ng, Earl Avramis, Elizabeth Seja, Arturo Villanueva, Tara A. McCannel, Akira Ishiyama, Johannes Czernin, Caius G. Radu, Xiaoyan Wang, David W. Gjertson, Alistair J. Cochran, Kenneth Cornetta, Deborah Jean Lee Wong, Paula Kaplan‐Lefko, Omid Hamid, Wolfram E. Samlowski, Peter A. Cohen, Gregory A. Daniels, Bijay Mukherji, Lili Yang, Jerome A. Zack, Donald B. Kohn, James R. Heath, John A. Glaspy, Owen N. Witte, David Baltimore, James S. Economou, Antoni Ribas - Clinical Cancer Research 2014 cited by 253

  16. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

    Authors: Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka‐Warzocha, Igor Puzanov, Alexander I. Spira, Daniel C. Cho, Shanhong Guan, Erika Puente-Poushnejad, Tuan Nguyen, Ute Hoch, Sue Currie, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael E. Hurwitz - Journal of Clinical Oncology 2021 cited by 81

  17. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

    Authors: Maria Schwaederlé, Barbara A. Parker, Richard B. Schwab, Gregory A. Daniels, David Piccioni, Santosh Kesari, Teresa Helsten, Lyudmila Bazhenova, J Moreno Romero, Paul T. Fanta, Scott M. Lippman, Razelle Kurzrock - Molecular Cancer Therapeutics 2016 cited by 184

  18. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy

    Authors: Yulian Khagi, Aaron M. Goodman, Gregory A. Daniels, Sandip Pravin Patel, Assuntina G. Sacco, James M. Randall, Lyudmila Bazhenova, Razelle Kurzrock - Clinical Cancer Research 2017 cited by 202

  19. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma

    Authors: Loren K. Mell, Kevin T. Brumund, Gregory A. Daniels, Sunil J. Advani, Kaveh Zakeri, Mary E. Wright, Sara-Jane N. Onyeama, Robert A. Weisman, Parag Sanghvi, Peter J. Martin, Aladar A. Szalay - Clinical Cancer Research 2017 cited by 138

  20. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

    Authors: Brendan D. Curti, Jon Richards, John Hyngstrom, Gregory A. Daniels, Mark B. Faries, Lynn G. Feun, Kim Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Robert H.I. Andtbacka - Journal for ImmunoTherapy of Cancer 2022 cited by 29

  21. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

    Authors: Mario Sznol, Pier Francesco Ferrucci, David Hogg, Michael B. Atkins, Pascal Wolter, Massimo Guidoboni, Célèste Lebbé, John M. Kirkwood, Jacob Schachter, Gregory A. Daniels, Jessica C. Hassel, Jonathan Cebon, Winald R. Gerritsen, Victoria Atkinson, L. Thomas, John McCaffrey, Derek G. Power, Dana Walker, Rafia Bhore, Joel Jiang, F. Stephen Hodi, Jedd D. Wolchok - Journal of Clinical Oncology 2017 cited by 294

  22. PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion

    Authors: Jennifer L. Hope, Dennis C. Otero, Eun‐Ah Bae, Christopher J. Stairiker, Ashley B. Palete, Hannah A. Faso, Michelle Lin, Monique L. Henriquez, Sreeja Biswas Roy, Hyungseok Seo, Lei Xue, Eric S. Wang, Savio Chow, Roberto Tinoco, Gregory A. Daniels, Kevin Y. Yip, Alexandre Rosa Campos, Jun Yin, Peter D. Adams, Anjana Rao, Linda M. Bradley - Cell Reports 2023 cited by 33

  23. Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells

    Authors: Gregory P. Botta, Joseph Chao, H. Ma, Michael G. Hahn, Gloria Sierra, Jie Jia, Amanda Y Hendrix, Joy Nolte Fong, Audrey Ween, Peter Vu, Aaron Miller, Michael Y. Choi, Benjamin Heyman, Gregory A. Daniels, Dan S. Kaufman, Catriona Jamieson, Zonghai Li, Ezra E.W. Cohen - Journal for ImmunoTherapy of Cancer 2024 cited by 31

  24. Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

    Authors: Christopher K. Bichakjian, Thomas Olencki, Sumaira Z. Aasi, Murad Alam, James Andersen, Rachel Blitzblau, Glen M. Bowen, Carlo M. Contreras, Gregory A. Daniels, Roy H. Decker, Jeffrey M. Farma, K.A. Fisher, Brian Gastman, Karthik Ghosh, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Manisha J. Loss, Daniel D. Lydiatt, Jane L. Messina, Kishwer S. Nehal, Paul Nghiem, Igor Puzanov, Chrysalyne D. Schmults, Ashok R. Shaha, Valencia D. Thomas, Yaohui G. Xu, John A. Zic, K Hoffmann, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2018 cited by 316